⚡ Syringe Tool
Metabolic & Fat Loss Preclinical / Research Only PubChem CID: 13711

AOD-9604: Clinical Mechanism, Dossier & Protocols

Modified C-terminal fragment of human Growth Hormone (hGH 177-191) with an added tyrosine, specifically stimulating lipolysis and inhibiting lipogenesis without affecting IGF-1 or blood glucose.

Reconstitution Guide Syringe Calculator BAC Water Guide

🔬 Molecular Architecture & Physical Specifications

Molecular Weight
1815.1 g/mol
Chemical Formula
C78H123N23O23S2
CAS Registry Number
221231-10-3
Elimination Half-Life
Approx. 30 minutes
Administration Route
Subcutaneous (SC), Oral (transmucosal)
NCBI PubChem Record
Amino Acid Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (Disulfide bridge Cys7-Cys14)

⚙️ Primary Mechanism of Action

Stimulates beta-3 adrenergic receptor pathways in adipose tissue, triggering the breakdown of fat stores (lipolysis) and preventing the formation of new fat (lipogenesis) without binding to standard hGH receptors.

💉 Research Dosage & Reconstitution Standard

Requires pharmaceutical-grade 0.9% benzyl alcohol Bacteriostatic Water to inhibit bacterial replication for multi-dose access.

Full Step-by-Step Guide →
Standard Vial Sizes
2mg, 5mg, 10mg
Target Research Dose
300mcg - 500mcg daily (administered fasted)
Administration Frequency
Once daily morning fasted or pre-cardio
💧 Dilution Standard: Reconstitute with sterile Bacteriostatic Water for Injection (USP). Aim stream gently along the vial glass wall to avoid foaming. Store reconstituted solution at 2°C to 8°C (36°F to 46°F) protected from light. Discard multi-dose punctured vials at 28 days pursuant to USP <797> standards. Never freeze reconstituted liquid.

⚠️ Contraindications & Documented Adverse Effects

Strict Contraindications

  • Active malignancy (precautionary)
  • Severe kidney impairment

Documented Side Effects

  • Mild redness at injection site
  • Headache
  • Euphoria/alertness

📚 Peer-Reviewed References & Authoritative Sources

Citations indexed in PubMed, National Center for Biotechnology Information (NCBI), and ClinicalTrials.gov.

1 VERIFIED CITATIONS
Journal of Endocrinology (2001; 170:79-89)
Demonstrated direct stimulation of beta-3 adrenergic lipolysis in adipocytes without causing insulin resistance or elevating serum IGF-1.
PMID: 11431141

Explore Related Research Modules

Access exact dilution guides, syringe unit calculators, and purity certificates for AOD-9604.

💧 AOD-9604 Dilution Guide ⚡ Syringe Reconstitution Tool Bacteriostatic Water Monograph Tested Vendor Directory Cycle Cost Calculator